Actively Recruiting
68Ga-grazytracer PET Assists in Diagnosing Pseudoprogression Following Immunotherapy in Lung Cancer.
Led by Ruijin Hospital · Updated on 2024-09-23
30
Participants Needed
1
Research Sites
79 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Currently, there are limited methods available in clinical practice to distinguish pseudoprogression after immunotherapy. Most patients rely on follow-up observations to monitor the disease, which does not meet clinical needs. 68Ga-grazytracer is a novel imaging agent targeting granzyme B. By detecting the concentration of granzyme B, it reflects the localization of cytotoxic T cells in the tumor region and their potential ability to kill tumor cells. This study aims to leverage the simplicity, non-invasiveness, visualization, and semi-quantitative advantages of 68Ga-grazytracer PET imaging to evaluate its effectiveness and feasibility in diagnosing pseudoprogression.
CONDITIONS
Official Title
68Ga-grazytracer PET Assists in Diagnosing Pseudoprogression Following Immunotherapy in Lung Cancer.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Lung cancer patients who develop lesion enlargement and/or new lesions after treatment with immune checkpoint inhibitors
- Pseudoprogression cannot be ruled out in clinical practice
- Lung cancer confirmed by pathology or cytology, regardless of pathological type
- Fully-informed written consent obtained from patients
- Patient ability to comply with protocol requirements
- Age 18-75 years
- Life expectancy of at least 6 months
You will not qualify if you...
- Patients with serious diseases deemed unsuitable for the study such as severe cardiopulmonary insufficiency, severe bone marrow suppression, or severe hepatic or renal insufficiency
- Intestinal perforation or complete intestinal obstruction
- Active phase of hepatitis B
- Pregnant women, women who are potentially pregnant, and nursing mothers
- Patients with poor compliance
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China, 200000
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here